Anika Therapeutics (ANIK) Misses Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.72 --0%
EPS Growth %: +115.4%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: +115.4%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.06), $0.02 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $26.17 million versus the consensus estimate of $28.13 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- Lockheed Martin wins $2.8B in Defense contracts for F-35, helicopters
- 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
